These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 7939432)

  • 1. Resistance to fluoroquinolones in Pseudomonas aeruginosa and Klebsiella pneumoniae.
    Rydberg J; Larsson C; Miörner H
    Scand J Infect Dis; 1994; 26(3):317-20. PubMed ID: 7939432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine to MIC values of ciprofloxacin in ciprofloxacin resistant gram-negative bacteria].
    Coban AY; Bayram Z; Sezgin FM; Durupinar B
    Mikrobiyol Bul; 2009 Jul; 43(3):457-61. PubMed ID: 19795621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
    Aubert G; Pozzetto B; Dorche G
    J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydrophobicity and serum sensitivity of Klebsiella pneumoniae treated with sub-MICs of quinolones.
    Hostacká A
    Microbios; 1997; 91(368-369):137-43. PubMed ID: 9523422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies.
    Grillon A; Schramm F; Kleinberg M; Jehl F
    PLoS One; 2016; 11(6):e0156690. PubMed ID: 27257956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The activity of four fluoroquinolones against strains of Pseudomonas aeruginosa with a different sensitivity pattern to ceftazidime and imipenem].
    Pascual A A; Joyanes P; Martínez-Martínez L; del Carmen Conejo M; Hernández G; Chaves J; Perea EJ
    Enferm Infecc Microbiol Clin; 2001 Nov; 19(9):432-4. PubMed ID: 11709121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial activity of the new quinolone CI-960 (PD 127391) against clinical isolates at a major tertiary care center in Saudi Arabia.
    Qadri SM; Abo-Askar H; Ueno Y
    Chemotherapy; 1992; 38(2):92-8. PubMed ID: 1317281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the emergence of resistance to lomefloxacin in vitro.
    Kanematsu M; Greenwood D
    Eur J Clin Microbiol Infect Dis; 1989 Aug; 8(8):741-5. PubMed ID: 2506046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro Activity of Sitafloxacin and Other Antibiotics against Bacterial Isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital.
    Tantisiriwat W; Linasmita P
    J Med Assoc Thai; 2017 Apr; 100(4):469-78. PubMed ID: 29912484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
    Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation of fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae from an infected Hickman catheter.
    López-Brea M; Alarcón T
    Eur J Clin Microbiol Infect Dis; 1990 May; 9(5):345-7. PubMed ID: 2197092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose.
    Well M; Naber KG; Kinzig-Schippers M; Sörgel F
    Int J Antimicrob Agents; 1998 Apr; 10(1):31-8. PubMed ID: 9624541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial susceptibilities of blood culture isolates obtained before and after the introduction of ciprofloxacin.
    Pieroni P; Goodfellow J; Reesor L; Louie M; Simor AE
    J Antimicrob Chemother; 1997 Mar; 39(3):419-22. PubMed ID: 9096194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant prevention concentrations of colistin used in combination with other antimicrobial agents against Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa clinical isolates.
    Choi MJ; Park YK; Peck KR; Ko KS
    Int J Antimicrob Agents; 2014 Nov; 44(5):475-6. PubMed ID: 25443890
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of fluoroquinolones in the promotion of alginate synthesis and antibiotic resistance in Pseudomonas aeruginosa.
    Piña SE; Mattingly SJ
    Curr Microbiol; 1997 Aug; 35(2):103-8. PubMed ID: 9216884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.
    Sutherland CA; Nicolau DP
    Clin Ther; 2015 Jul; 37(7):1564-71. PubMed ID: 26088525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
    Kowalski RP; Pandya AN; Karenchak LM; Romanowski EG; Husted RC; Ritterband DC; Shah MK; Gordon YJ
    Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
    Cetinkaya E; Coban AY; Durupinar B
    Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa.
    Jalal S; Wretlind B
    Microb Drug Resist; 1998; 4(4):257-61. PubMed ID: 9988043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.